UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
September 25, 2007
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
BIOPHARMACEUTICALS LTD. AGM / EGM POSTPONED UNTIL OCTOBER 2,
2007
Valley
Cottage, New York, September 25, 2007 -
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces today
that
its Annual General Meeting (“AGM”) and Extraordinary General Meeting (“EGM”) was
postponed for one week in accordance with its articles of association due
to the
absence of a quorum. The postponed AGM and EGM will take place at the Company,
Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100 at 4:00
pm and
4:30pm, respectively on October 2, 2007.
Any
proxy
votes received at any time up to 48 hours prior to the postponed AGM and
EGM
will be included in the total votes counted for the AGM and EGM. Those
shareholders who have a valid “proof of ownership” in Israel or a letter of
representation from Computershare, the Company’s registrars, and attend the
meeting in person will also be permitted to vote.
As
a
result of postponing the EGM, the Company anticipates that the time and
date for
the cancellation of the listing of its Ordinary Shares from the Official
List of
the United Kingdom Listing Authority, being not less than 20 business days
from
the date of the EGM as required by the United Kingdom Listing Rules, is
now 8:00
am (London Time) on October 31, 2007.
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the development of therapeutics
for the treatment of neuropathic pain and hepatitis C. XTL is developing
Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the
treatment
of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
hepatitis C small molecule inhibitors. XTL also has an active in-licensing
and
acquisition program designed to identify and acquire additional drug candidates.
XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges
(NASDAQ: XTLB; LSE: XTL; TASE: XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended,
the
registrant has duly caused this report to be signed on its behalf by
the
undersigned, thereunto duly authorized.
|
XTL
BIOPHARMACEUTICALS LTD.
|
||
| |
|
|
|
Date:
September 25, 2007
|
By: | /s/ Ron Bentsur |
|
Ron
Bentsur
|
||
|
Cheif
Executive Officer
|
||
3